Shots:
Nxera Pharma, through its subsidiary Nxera Pharma Japan, entered an exclusive license, supply and commercialization agreement with Synmosa Biopharma for Quviviq (daridorexant), a treatment for insomnia, across Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia and New Zealand
Synmosa will lead regulatory approvals, market access, marketing, distribution and sales across the eight markets, while…
